Cart
sales@molnova.com
GDC0575 monohydrochloride
CAS No. 1196504-54-7
GDC0575 monohydrochloride( —— )
Catalog No. M27878 CAS No. 1196504-54-7
GDC-0575 is a potent and selective inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2?nM. GDC-0575 specifically binds to and inhibits Chk1; this may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases, which permits the cells to undergo DNA repair prior to entry into mitosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 80 | Get Quote |
|
| 5MG | 115 | Get Quote |
|
| 10MG | 165 | Get Quote |
|
| 25MG | 296 | Get Quote |
|
| 50MG | 426 | Get Quote |
|
| 100MG | 608 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGDC0575 monohydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionGDC-0575 is a potent and selective inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2?nM. GDC-0575 specifically binds to and inhibits Chk1; this may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases, which permits the cells to undergo DNA repair prior to entry into mitosis.
-
DescriptionGDC-0575 is a potent and selective inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2?nM. GDC-0575 specifically binds to and inhibits Chk1; this may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases, which permits the cells to undergo DNA repair prior to entry into mitosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetChk
-
RecptorhSGLT2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1196504-54-7
-
Formula Weight414.73
-
Molecular FormulaC16H21BrClN5O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCl.N[C@@H]1CCCN(C1)c1c(Br)cnc2[nH]cc(NC(=O)C3CC3)c12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Miao Z, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013 Feb;41(2):445-56.
molnova catalog
related products
-
NSC-109555 ditosylat...
A potent, selective, reversible, ATP-competitive Chk2 inhibitor with IC50 of 0.2 uM.
-
VRX-0466617
A potent and selective Chk2 inhibitor with Ki/IC50 of 11 nM/120 nM; shows no inhibitory effect on Chk1 (>100 uM).
-
CCT-245737
A highly potent, selective, ATP-competitive inhibitor of Chk1 with IC50 of 1.3 nM; weak inhibition on Chk2 (IC50=2440 nM).
